Blood cancers

ASCO 21: Novel BCL-2 inhibitor could offer alternative to venetoclax in RR CLL

With a daily ramp-up schedule that may be more patient “user friendly” and a favourable preliminary safety profile, the novel BCL-2 inhibitor lisaftoclax could offer an alternative to venetoclax for patients with relapsed/refractory (R/R) CLL and other haematologic malignancies Presenting findings from the first-in-human study of lisaftoclax this week at ASCOs virtual annual scientific meeting, ...

Already a member?

Login to keep reading.

© 2022 the limbic